Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma

BACKGROUND: Only a fraction of patients with malignant pleural mesothelioma (MPM) will respond to chemo- or immunotherapy. For the majority, the condition will irremediably relapse after 13 to 18 months. In this study, we hypothesized that patients’ outcome could be correlated to their immune cell p...

Descripción completa

Detalles Bibliográficos
Autores principales: Willems, Mégane, Scherpereel, Arnaud, Wasielewski, Eric, Raskin, Jo, Brossel, Hélène, Fontaine, Alexis, Grégoire, Mélanie, Halkin, Louise, Jamakhani, Majeed, Heinen, Vincent, Louis, Renaud, Duysinx, Bernard, Hamaidia, Malik, Willems, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070849/
https://www.ncbi.nlm.nih.gov/pubmed/37026006
http://dx.doi.org/10.3389/fimmu.2023.1148798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070849/
https://www.ncbi.nlm.nih.gov/pubmed/37026006
http://dx.doi.org/10.3389/fimmu.2023.1148798

Ejemplares similares